Portola Pharmaceuticals Inc (PTLA) 24.80 $PTLA
Portola Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014
GlobeNewswire - Wed Jul 30, 3:00PM CDT
Portola Pharmaceuticals, Inc. (Nasdaq
TLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2014 and provide a general business overview on Wednesday, August 6, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Why Portola Pharmaceuticals Inc. Stock Swooned
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 07, 3:29PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Portola Pharmaceuticals , a clinical-stage...
Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo for Phase 3 Studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban
GlobeNewswire - Mon Jul 07, 1:10PM CDT
-- Phase 3 Collaboration Agreements in Place With All Direct Factor Xa Inhibitor Manufacturers While Portola Retains All Rights to Andexanet Alfa --
CMC Biologics Enters into Commercial Supply Agreement with Portola Pharmaceuticals for Manufacturing of First-In-Class Factor Xa Inhibitor Antidote Andexanet Alfa
PR Newswire - Wed Jul 02, 4:00PM CDT
CMC Biologics, Inc., a global leader in process development and contract manufacturing, today announced that it has entered in to a Commercial Supply Agreement with Portola Pharmaceuticals, a biopharmaceutical company for the development of andexanet alfa, a potential first-in class Factor Xa inhibitor antidote in Phase 3 ANNEXATM (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors) studies. Andexanet alfa is designed to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are experiencing a major bleeding episode or who require emergency surgery.
Portola Pharmaceuticals, Inc. (PTLA) in Focus Stock Up 5.72% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 7:44AM CDT
Portola Pharmaceuticals, Inc. (PTLA) was a big mover last session, as the company saw its shares gain nearly 6% on the day.
Portola Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference
GlobeNewswire - Thu Jun 12, 3:00PM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced that William Lis, chief executive officer, will present at the 2014 Wells Fargo Securities Healthcare Conference on Wednesday, June 18, at 8:20 a.m. Eastern Time in Boston.
Can the Rally in Portola Pharma (PTLA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 8:55AM CDT
Can the Rally in Portola Pharma (PTLA) Shares Continue?
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell
Wednesday’s Top Biotech Stories: Orexigen, Portola, and Regeneron
Leo Sun, The Motley Fool - Motley Fool - Wed Jun 11, 8:11AM CDT
Let's take a look at three stocks -- Orexigen Therapeutics , Portola Pharmaceuticals , and Regeneron -- which could all loom large in Wednesday's health care headlines. Orexigen's PDUFA date for NB32/Contrave gets extended by three months ...
Portola Pharmaceuticals Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxaparin
GlobeNewswire - Wed Jun 11, 7:00AM CDT
--Data Extend the Potential for Andexanet as an Antidote Beyond
Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2014
M2 - Tue Jun 10, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ch2twj/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Merck & Co., Inc. - Infinity Pharmaceuticals, Inc. - Celltrion, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - ImmunoGen, Inc. - Genmab A/S - Celgene Corporation - Incyte Corporation - Immunomedics, Inc. - Idera Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. For more information visit http://www.researchandmarkets.com/research/ch...fuse_large
Venous Thromboembolism - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ns5n4/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/5ns5n4/venous
Follicular Lymphoma - Pipeline Review, H1 2014
M2 - Thu May 29, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97lh2b/follicular) has announced the addition of the "Follicular Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Follicular Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Follicular Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AbbVie - Accentia Biopharmaceuticals - AmpliMed Corporation - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb Company - Celgene Corporation - CureTech - F. Hoffmann-La Roche - Genmab - Gilead Sciences - ImmunoGen - Immunomedics - Infinity Pharmaceuticals - MENTRIK Biotech - Memgen - Merck & Co - Millennium Pharmaceuticals - Novartis - Pharmacyclics - Portola Pharmaceuticals - ProNAi Therapeutics - Sandoz - Xiamen Amoytop Biotech For more information visit http://www.researchandmarkets.com/research/97lh2b/follicular
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu May 29, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r7tzzp/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from a proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsed Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AbbVie - AstraZeneca - Boehringer Ingelheim - Celgene - Emergent BioSolutions - Genmab - GlaxoSmithKline - Infinity Pharmaceuticals - MorphoSys - Noxxon Pharma - Pharmacyclics - Portola Pharmaceuticals - SBI Biotech - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r7...ed_chronic
An Interview With Portola Pharmaceuticals CEO Bill Lis
Max Macaluso, The Motley Fool - Motley Fool - Fri Mar 28, 11:22AM CDT
Portola Pharmaceuticals is relatively new to biotech investors and was one of many biotechs to IPO last year. In an effort to better understand the company's pipeline and upcoming catalysts, analyst Max Macaluso recently spoke with the company's...
Portola Pharmaceuticals Initiates Phase 2 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, and Factor Xa Inhibitor Edoxaban
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced that it has initiated a Phase 2 proof-of-concept study to evaluate andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent, as a reversal agent for Daiichi Sankyo's oral, once-daily, direct Factor Xa inhibitor edoxaban in healthy volunteers. Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are suffering a major bleeding episode or who require emergency surgery. The Company is pursuing an Accelerated Approval pathway for andexanet alfa, which is the only agent that has demonstrated reversal of the anticoagulation activity of Factor Xa inhibitors as measured by biomarkers, including anti-Factor Xa activity, in human studies.
Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 19, 8:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Horizon Pharma , ...
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
GlobeNewswire - Wed Mar 19, 7:15AM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced that it has initiated a Phase 3 study of andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent. The study will evaluate the safety and efficacy of andexanet alfa with Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.'s (NYSE: PFE) Factor Xa inhibitor Eliquis(apixaban). Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are suffering a major bleeding episode or who require emergency surgery. The Company is pursuing an Accelerated Approval pathway for andexanet alfa, which is the only agent that has demonstrated reversal of the anticoagulation activity of Factor Xa inhibitors as measured by biomarkers, including anti-Factor Xa activity, in human studies.
Portola Pharmaceuticals elects John H. Johnson to board
M2 - Wed Mar 19, 6:42AM CDT
Biopharmaceutical company Portola Pharmaceuticals (NasdaqGS TLA) revealed on Tuesday the addition of John H. Johnson to its board of directors, effective 26 March 2014.
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
GlobeNewswire - Tue Mar 18, 7:00AM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced the appointment of John H. Johnson to its board of directors effective March 26, 2014. Mr. Johnson currently serves as chairman, president and chief executive officer of Dendreon Corporation.
Portola Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014
GlobeNewswire - Wed Jul 30, 3:00PM CDT
Portola Pharmaceuticals, Inc. (Nasdaq
TLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2014 and provide a general business overview on Wednesday, August 6, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Why Portola Pharmaceuticals Inc. Stock Swooned
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 07, 3:29PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Portola Pharmaceuticals , a clinical-stage...
Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo for Phase 3 Studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban
GlobeNewswire - Mon Jul 07, 1:10PM CDT
-- Phase 3 Collaboration Agreements in Place With All Direct Factor Xa Inhibitor Manufacturers While Portola Retains All Rights to Andexanet Alfa --
CMC Biologics Enters into Commercial Supply Agreement with Portola Pharmaceuticals for Manufacturing of First-In-Class Factor Xa Inhibitor Antidote Andexanet Alfa
PR Newswire - Wed Jul 02, 4:00PM CDT
CMC Biologics, Inc., a global leader in process development and contract manufacturing, today announced that it has entered in to a Commercial Supply Agreement with Portola Pharmaceuticals, a biopharmaceutical company for the development of andexanet alfa, a potential first-in class Factor Xa inhibitor antidote in Phase 3 ANNEXATM (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors) studies. Andexanet alfa is designed to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are experiencing a major bleeding episode or who require emergency surgery.
Portola Pharmaceuticals, Inc. (PTLA) in Focus Stock Up 5.72% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 7:44AM CDT
Portola Pharmaceuticals, Inc. (PTLA) was a big mover last session, as the company saw its shares gain nearly 6% on the day.
Portola Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference
GlobeNewswire - Thu Jun 12, 3:00PM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that William Lis, chief executive officer, will present at the 2014 Wells Fargo Securities Healthcare Conference on Wednesday, June 18, at 8:20 a.m. Eastern Time in Boston. Can the Rally in Portola Pharma (PTLA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 8:55AM CDT
Can the Rally in Portola Pharma (PTLA) Shares Continue?
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell
Wednesday’s Top Biotech Stories: Orexigen, Portola, and Regeneron
Leo Sun, The Motley Fool - Motley Fool - Wed Jun 11, 8:11AM CDT
Let's take a look at three stocks -- Orexigen Therapeutics , Portola Pharmaceuticals , and Regeneron -- which could all loom large in Wednesday's health care headlines. Orexigen's PDUFA date for NB32/Contrave gets extended by three months ...
Portola Pharmaceuticals Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxaparin
GlobeNewswire - Wed Jun 11, 7:00AM CDT
--Data Extend the Potential for Andexanet as an Antidote Beyond
Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2014
M2 - Tue Jun 10, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ch2twj/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Merck & Co., Inc. - Infinity Pharmaceuticals, Inc. - Celltrion, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - ImmunoGen, Inc. - Genmab A/S - Celgene Corporation - Incyte Corporation - Immunomedics, Inc. - Idera Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. For more information visit http://www.researchandmarkets.com/research/ch...fuse_large
Venous Thromboembolism - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ns5n4/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/5ns5n4/venous
Follicular Lymphoma - Pipeline Review, H1 2014
M2 - Thu May 29, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97lh2b/follicular) has announced the addition of the "Follicular Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Follicular Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Follicular Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AbbVie - Accentia Biopharmaceuticals - AmpliMed Corporation - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb Company - Celgene Corporation - CureTech - F. Hoffmann-La Roche - Genmab - Gilead Sciences - ImmunoGen - Immunomedics - Infinity Pharmaceuticals - MENTRIK Biotech - Memgen - Merck & Co - Millennium Pharmaceuticals - Novartis - Pharmacyclics - Portola Pharmaceuticals - ProNAi Therapeutics - Sandoz - Xiamen Amoytop Biotech For more information visit http://www.researchandmarkets.com/research/97lh2b/follicular
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu May 29, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r7tzzp/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from a proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsed Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AbbVie - AstraZeneca - Boehringer Ingelheim - Celgene - Emergent BioSolutions - Genmab - GlaxoSmithKline - Infinity Pharmaceuticals - MorphoSys - Noxxon Pharma - Pharmacyclics - Portola Pharmaceuticals - SBI Biotech - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r7...ed_chronic
An Interview With Portola Pharmaceuticals CEO Bill Lis
Max Macaluso, The Motley Fool - Motley Fool - Fri Mar 28, 11:22AM CDT
Portola Pharmaceuticals is relatively new to biotech investors and was one of many biotechs to IPO last year. In an effort to better understand the company's pipeline and upcoming catalysts, analyst Max Macaluso recently spoke with the company's...
Portola Pharmaceuticals Initiates Phase 2 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, and Factor Xa Inhibitor Edoxaban
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that it has initiated a Phase 2 proof-of-concept study to evaluate andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent, as a reversal agent for Daiichi Sankyo's oral, once-daily, direct Factor Xa inhibitor edoxaban in healthy volunteers. Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are suffering a major bleeding episode or who require emergency surgery. The Company is pursuing an Accelerated Approval pathway for andexanet alfa, which is the only agent that has demonstrated reversal of the anticoagulation activity of Factor Xa inhibitors as measured by biomarkers, including anti-Factor Xa activity, in human studies. Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 19, 8:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Horizon Pharma , ...
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
GlobeNewswire - Wed Mar 19, 7:15AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that it has initiated a Phase 3 study of andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent. The study will evaluate the safety and efficacy of andexanet alfa with Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.'s (NYSE: PFE) Factor Xa inhibitor Eliquis(apixaban). Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are suffering a major bleeding episode or who require emergency surgery. The Company is pursuing an Accelerated Approval pathway for andexanet alfa, which is the only agent that has demonstrated reversal of the anticoagulation activity of Factor Xa inhibitors as measured by biomarkers, including anti-Factor Xa activity, in human studies. Portola Pharmaceuticals elects John H. Johnson to board
M2 - Wed Mar 19, 6:42AM CDT
Biopharmaceutical company Portola Pharmaceuticals (NasdaqGS
TLA) revealed on Tuesday the addition of John H. Johnson to its board of directors, effective 26 March 2014. Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
GlobeNewswire - Tue Mar 18, 7:00AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced the appointment of John H. Johnson to its board of directors effective March 26, 2014. Mr. Johnson currently serves as chairman, president and chief executive officer of Dendreon Corporation. 
